Kezdőlap・Részvénylista・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Nyitva

SzektorEgészségügy

3.34 0.91

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.2800000000000002

Maximum

3.43

Fő mutatók
By Trading Economics
Bevétel	-2.4M -21M
Értékesítés	-8.8M 1.4M
P/E Szektor átlag	22.5 57.366
Egy részvényre jutó nyereség	-0.09
Profit margin	-1,457.405
Munkavállalók	69
EBITDA	-2.4M -20M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+285.54% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 5.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	27M 717M
Előző nyitás	2.43
Előző zárás	3.34

Hangulat hírek alapján

By Acuity

50%

160 / 340 Rangsor szerint Healthcare

CytomX Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 25. 19:56 UTC

CytomX Therapeutics is trading higher amid positive market conditions and lower crude oil prices, which have decreased treasury yields and boosted investor sentiment.

2026. aug. 24. 19:26 UTC

CytomX Therapeutics is trading higher, reflecting gains since Friday's close. Earlier, shares peaked with a gain before pulling back to a modest advance.

2026. aug. 21. 19:46 UTC

CytomX Therapeutics Inc. is gaining during Friday's session, despite earlier volatility. No specific company news was identified to explain today's price movement.

2026. aug. 20. 21:01 UTC

CytomX Therapeutics Inc shares are higher in after-market hours, reflecting unusual trading activity. The stock is positioned around the midpoint of its one-month range.

2026. aug. 19. 20:02 UTC

CytomX Therapeutics is trading higher during Wednesday's session, continuing a strong upward move since Tuesday's close amid notable volatility.

2026. aug. 14. 19:36 UTC

Social Media

CytomX Therapeutics is higher as social media highlights its undervaluation, with a suggested price target of $6-7 ahead of year-end data releases.

2026. aug. 13. 22:01 UTC

CytomX Therapeutics shares are higher in after-market trading, supported by broader market strength and a record closing high for the S&P 500.

2026. aug. 12. 19:46 UTC

CytomX Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close, supported by positive sentiment from the recent inflation report.

2026. aug. 11. 23:21 UTC

CytomX Therapeutics Inc. shares are higher in after-market trading, reaching 1.45% above Tuesday's close amid strong performance relative to its moving average.

2026. aug. 10. 23:31 UTC

CytomX Therapeutics Inc shares are lower in after-market hours after earlier volatility. Broader market sentiment remains cautious amid geopolitical tensions in the Strait of Hormuz.

2026. aug. 7. 19:16 UTC

Social Media

News

CytomX Therapeutics expands collaboration with Regeneron on immunotherapies and updates on Varseta-M program, boosting sentiment amid a rising Biotechnology sector.

2026. aug. 6. 22:02 UTC

Social Media

News

CytomX Therapeutics shares declined in after-market hours following a significant revenue miss of $1.418 million against expectations of $12.308 million.

2026. júl. 31. 20:06 UTC

CytomX Therapeutics Inc shares declined sharply during Friday's session, reversing earlier gains and trading well below the 20-day moving average. No specific news was identified.

2026. júl. 29. 19:47 UTC

CytomX Therapeutics shares are lower as traders await the Federal Reserve's interest rate decision, contributing to mixed performance across major U.S. indices.

2026. júl. 28. 17:46 UTC

CytomX Therapeutics shares are lower today, reflecting a broader cautious tone across Asian markets. The stock remains near its one-month low.

2026. júl. 27. 23:26 UTC

CytomX Therapeutics shares are higher in after-market hours, though no specific news was identified. Broader positive sentiment in European indices may be influencing investors.

2026. júl. 21. 19:56 UTC

CytomX Therapeutics Inc shares are lower today, continuing a downward trend. The stock remains significantly below its 20-day moving average.

Társak összehasonlítása

Árváltozás

CytomX Therapeutics Inc Előrejelzés

Célár

By TipRanks

285.54% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 12.8 USD 285.54%

Magas 16 USD

Alacsony 11 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)CytomX Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

5 ratings

Vétel

Tartás

Eladás

5 Wall Street elemző célárain alapulva a(z)CytomX Therapeutics Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

160 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.